The oral route is the preferential route of drug delivery in humans. However, effective delivery through the gastrointestinal tract is often hampered by the low permeability of the intestinal epithelium. One possibility to overcome this problem is the encapsulation of drugs inside nanoparticulate systems containing targeting moieties with cell invasive properties. 
Introduction
Over the past decades, multiple biotechnology-based drugs such as peptide and protein therapeutics (e.g. vaccines, hormones, antibodies) became available and many more are expected in the future. Currently, the most effective and most common delivery of these biopharmaceuticals is the parenteral route of administration (injection and intravenous infusion). Yet, in view of its convenience and patient acceptance, oral delivery is the main mode of choice [1, 2] : (i) oral systems are easy to administer (very important in situations where delivery to mass populations is required) and avoids pain and discomfort, (ii) a large variety of dosage forms can be applied and (iii) vaccines, which are delivered orally, generate mucosal immunity, e.g. against enteric pathogens [1] . However, despite the success in oral delivery of small therapeutic molecules such as antibiotics and traditional chemically synthesized compounds, little success has been achieved with macromolecule biopharmaceuticals such as therapeutic proteins. Their delivery through the gastrointestinal (GI) tract is impeded by several biological barriers which lead to a poor bioavailability. The high molecular weight (>700 Da) and hydrophilicity of macromolecular drugs affects permeation and transcellular absorption by passive diffusion.
Another major problem is the low permeability of the intestinal epithelial layer. Uptake of drugs by the paracellular pathway, i.e. through intracellular spaces between adjacent cells of the epithelium, is largely inhibited by tight cell-cell junctions, which allow the physical separation of the host from the external environment. The thick mucus layer covering the intestinal epithelium and the different cell composition of the intestinal layer, including enterocytes, goblet cells, Paneth cells, endocrine cells and M cells also hamper efficient targeting and uptake of drugs. Another important problem is the degradation or inactivation of the delivered drugs in the harsh environment (e.g. strong pH variations, large variety of proteases and other lytic enzymes) of the GI tract, particularly in the stomach and duodenum, or en-route to the site of action. Moreover, inefficient absorption of all drug classes is a problem in patients suffering from GI diseases [3] . As a consequence, high doses of biopharmaceuticals are often required to assure efficient absorption from the epithelium.
There are several technologies that aim to circumvent the above mentioned problems. These include protection and release modification systems where the drug is protected from the harsh environment and released at a particular time following administration. Delivery across the intestinal epithelium could be improved by the development of inert drug carrier systems with targeting molecules with bioadhesive and cell invasive properties. Over the past years, particulate systems like nanoparticles (particulate dispersions with the size of 10-1000 nm) have shown to be very useful for the targeted delivery of various types of drug molecules. Nanoparticles can be made of different materials, such as proteins, polysaccharides or synthetic polymers, and the drug is dissolved, encapsulated or attached to the nanoparticle surface. Furthermore, it was shown that encapsulation of the drug inside nanoparticulate systems can increase the stability of the drug and facilitate controlled and sustained release of the compound [4, 5] . A potential pitfall in the use of nanoparticles is that (i) they can directly transit the GI tract and are rapidly eliminated, or (ii) they provide cellular attachment to sites where cellular internalization and transfer through the intestinal layer may not automatically follow. Thus, for the successful delivery of the drug, the carrier system must promote adherence to sites of the intestinal epithelium that allow efficient absorption and subsequent transcytosis of the nanoparticles into subepithelial tissues. Intestinal "sites" particularly suitable for particle absorption are M cells. M cells are found in the regions of the follicle-associated epithelium (FAE) that cover the lymphoid structures associated with the mucosal immune system, such as Peyer´s patches and isolated lymphoid follicles (ILFs) [6] . They mainly act as antigen sampling cells delivering pathogenic agents and other antigens from the gut lumen to the underlying lymphoid tissues. In contrast to the columnar epithelial cells, they possess a unique glycosylation pattern and their apical membrane is covered by irregular and much broader microvilli, which are thought to facilitate particle adherence and subsequent endo-and phagocytic processes.
Moreover, it could be shown that the apical membranes of M cells express β 1 -integrins -adhesion molecules that are only expressed at the basolateral membranes of adjacent enterocytes [7] [8] [9] . Hence, one way to considerably improve adhesion, endo-and transcytosis of drug-containing nanoparticles would be to coat them with ligands capable of interacting with M cell-specific surface components, e.g. glycoproteins or β 1 -integrins. In fact, several studies reported that lectins, such as tomato and bean lectin, which selectively bind to sugar moieties, can be used for site-specific targeting of nanoparticles to the surface of M cells and enterocytes [10, 11] . Tight and long-term adhesion leads to a longer retention period of the particle drug complex at the epithelial cell surface and induces participation in vesicular uptake and transport processes, a prerequisite for oral absorption. Bioinvasion of the drug delivery system could be further improved by the use of viral and bacterial ligands shown to promote host cell entry by the pathogen [12, 13] . In particular invasion factors (invasins) of invasive enteropathogenic bacteria have gained great interest for the development of bioinvasive drug delivery systems. Many of the identified bacterial invasins promote fast and efficient cell entry via β 1 -integrins and trigger transcytosis of the bacteria through the M cells of the intestinal epithelial layer [14, 15] The best-characterized bacterial uptake systems are those found in species of the genera Listeria, Salmonella, Shigella or Yersinia. The different types and molecular functions of the bacterial uptake pathways are introduced in the following chapters and their potential for the development of site-specific bioinvasive drug delivery systems is discussed.
Invasion strategies of bacterial pathogens
The ability to invade and translocate across the intestinal barrier is a typical feature of enteric pathogens. Invasion into cells of the intestinal layer is important to (a) avoid an attack of the host immune system, e.g. by antimicrobial peptides or immunoglobulins, like IgA which are secreted in the gut lumen, and (b) to initiate transcytosis and colonization of deeper host tissues which is crucial to establish and maintain the infection. Importance of the invasion systems is further supported by the fact that most of the enteroinvasive pathogens, including Listeria and Yersinia, produce multiple host cell uptake systems, which enable them to induce their own phagocytosis in cells that are normally non-phagocytic (e.g. epithelial cells) [16] .
A prerequisite for the invasion of eukaryotic cells is the expression of virulence factors, which promote tight adhesion to host cell surface components [17, 18] . Bacterial invasion proteins either remain anchored in the bacterial membrane or are released via a specialized secretion system. They predominantly interact with specific host cell receptors or proteins of the extracellular matrix (ECM), and trigger local actin cytoskeleton rearrangements within the host cells. This leads to the formation of membrane protrusions which engulf and enclose the pathogen in a membrane-bound vacuole, a process called "induced endocytosis/phagocytosis" [18] [19] [20] .
Depending on the invasion factor two distinct uptake strategies are initiated: (A) the trigger mechanism and (B) the zipper mechanism (Fig. 1) .
(A) trigger mechanism
The trigger mechanism is an invasion process based on the bacterial type III secretion system (T3SS). Here, bacteria-host contact is accomplished by components of the T3SS, which deliver effector proteins into the host cell to initiate cytoskeletal rearrangements [21, 22] . This invasion process can be subdivided into four distinct steps: (i) the stand-by state, in which the effectors are stored in the bacterial cytoplasm, (ii) bacteria-host cell contact which triggers the secretory processes, (iii) manipulation of signaling proteins (e.g. small Rho GTPases) by delivered effector proteins which leads to the formation of numerous filo-and lamellipodia, called membrane ruffling (Fig. 1) , and (d) closing of the membrane invaginations and engulfment of the bacteria [13] .
The triggering mechanism is used by species of the genera Salmonella and Shigella [21, 22] . They are both transmitted by the fecal-oral route, cross the epithelial barrier of the gut mainly through M cells and cause severe gastrointestinal diseases [23, 24] . By expressing a T3SS the bacteria are able to deliver a subset of different effector proteins (Shigella: Ipas = invasion plasmid antigens; Salmonella: Sips = Salmonella invasion proteins), which initialize the internalization process [25, 26] . After breaching the epithelial barrier, they invade and replicate in macrophages and spread to other host cells thus establishing a systemic infection. In contrast to Salmonella, which resides and replicates in endocytic vacuoles, Shigella lyses the phagosome and replicates in the host cell cytoplasm [27, 28] . Although, T3SS-mediated cell uptake is very efficient and allows uptake of close-by "non-invasive" particles, use of this pathway for drug delivery systems is hampered by the fact that cell adhesion and actin rearrangements important for the invasion process are promoted by separate components.
(B) zipper mechanism
The zipper mechanism constitutes a receptor-mediated internalization process [29] ( Fig. 1) . This entry pathway can be divided into three distinct steps: (i) contact of a membrane-anchored bacterial ligand (invasin) with a specific host cell receptor, (ii) ligand-induced activation of the cell receptor (e.g. by receptor clustering or/and phosphorylation) which triggers certain signaling cascades leading to actin cytoskeleton rearrangements and the formation of a phagocytic cup, and (iii) engulfment and enclosure of the pathogen into a membrane-bound vacuole (bacterial phagosome). This process is very efficient, specific for the ligand-coated object and is solely initiated by the interaction of the bacterial ligand with the host cell receptor.
Listeria monocytogenes and enteropathogenic Yersinia species are representatives which use the zipper mechanism to promote host cell uptake [13, 29, 30] . L. As the "zippering"-inducing bacterial invasion factors provide one of the most direct, specific and efficient manners of host cell invasion, they are of particular interest for use in the oral delivery of bioactive molecules and gene-based vaccines [37] [38] [39] . Apart from the Listeria and Yersinia uptake factors, other "zippering"-inducing bacterial invasion factors have been identified in non-enteric pathogens [19, 20] .
They were found to promote colonization of various different host tissues and/or organs which make them also attractive of therapeutic products. A selection of the most potential bacterial invasins for drug delivery systems is given in Table 1 , and described in further detail in the following chapter.
Bacterial invasins -modular factors made for host cell entry
Since the host cell adhesion and entry process represents the first critical step for the pathogen to initiate and establish an infection, it is not surprising that most bacterial invasins are very efficient and highly specific for certain cell types, i.e. for those expressing the appropriate host cell receptor. Bacterial invasion factors could be identified in Gram-positive and Gram-negative bacteria [13, 19, 20] . They are very diverse and belong to different families of surface proteins (Fig. 1B) , which often contain domains that are either homologous to each other or homologous to eu- (Fig. 2, Table 1 ) [19] . [52] . Opa/Opc proteins are also able to interact with certain ECM-proteins, e.g. vitronectin (Vn) and fibronectin (Fn) bound to  5  1 and  V  3 integrins. This so-called "bridging mechanism" leads to integrin receptor clustering and activation, and triggers actin rearrangements required for uptake [53] . Moreover, several carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) serve as receptors for neisserial Opa proteins [54] . Upon CEACAM binding, Opa-expressing bacteria can be internalized by several cell types, including professional phagocytes, epithelial and endothelial cells [55] . Taken together, Neisseria species use a versatile set of invasin-receptor interactions to enable the internalization of the pathogen into different human cell types. (Fig. 2, 3) . Both invasion factors belong to very different groups of autotransporter adhesins/invasins, and their cell binding specificity and invasion efficiency can strongly differ among the different species due to small variations in their cell binding domains [60] .
YadA is a trimeric protein that forms lollipop-shaped projections which cover the bacterial surface [61] . The C-terminal membrane anchor domain is responsible for oligomerization and translocation of the N-terminal "passenger" domain (Fig. 1B, 2) .
The passenger domain is composed of a stalk and a head region which mediate binding to Fn, different collagens (Co) and laminins [36, 61, 62] . Variations within the head region can change the efficiency of cell entry through ECM-bound β 1 -integrins.
It has been reported that an additional 21 aa region in the YadA head domain of Y.
pseudotuberculosis mediates a much stronger adhesion to Fn bound on α 5 β 1 -integrin receptors, but a weaker interaction to co-bound α 2 β 1 -integrins compared to YadA of Y. enterocolitica, which results in a much higher cell uptake rate [63] .
The outer membrane protein invasin (InvA) interacts directly with different members of the  1 -integrin family [64] . Most strikingly, this interaction occurs with a substantially higher binding affinity compared with their natural ligands (e.g. Fn), and promotes host cell uptake which is much more efficient than uptake mediated through ECM-bridging (e.g. Fn-bound β 1 -integrins) [65] [66] [67] . InvA from Y. pseudotuberculosis consists of an N-terminal β-barrel structure that anchors the protein in the outer membrane (Fig. 3) . The extracellular C-terminal domain forms an elongated, rod-like structure composed of four immunoglobulin-like domains (D1-D4) and the cell-binding domain D5 (Fig. 3) [68] . The last 192 C-terminal amino acids are sufficient for receptor binding and bacterial uptake by epithelial cells [69] , and an aspartate residue at position 911 within D5 was shown to be crucial for the internalization process [70] . Since domain D5 is structurally very similar to the integrin binding domain in Fn, it is assumed that this residue mimics the conserved aspartate from the RGD motif of the natural ligand Fn for integrin binding [71] [72] [73] . Furthermore, it could be shown that domain D2 of InvA triggers multimerization of the protein. This triggers clustering of the integrin receptors and enhances the efficiency of the uptake process [74] . InvA-expressing bacteria are specifically targeted to β 1 -integrins expressing M cells and are rapidly and efficiently transported into subepithelial layers [7] . Thus, it is not surprising that mainly InvA has been used to test its use for bioinvasive drug carrier systems. Although gut proteases target invasin in vivo [78] , it is possible to use smaller and more resistant protein fragments harboring only the invasive domain of
Use of bacterial invasion factors for drug delivery
InvA. In 1998, it was shown that latex particles coupled with a 192-residue InvA fragment are internalized into host cells and distributed systemically in rats [77, 79, 80] . InvA was further used for different types of gene carriers. For example, engineered InvA-coated E. coli and soluble InvA fragments attached to DNA-binding proteins were used for gene delivery into cultured cells [81] [82] [83] [84] [85] [86] .
Several factors have been shown to influence InvA-mediated drug delivery systems and can be used and/or must be considered in order to optimize the system.
For the production of a nanoparticle-based drug delivery system, large amounts of the protein are required. Recombinant invasin fragments can easily be produced in high amounts by genetic engineering. Nonetheless, the fragments need to be coated onto the carrier particle in a way that does not compromise their bioactivity. This means covalent attachment methods must be optimized to ensure correct orientation of the invasive ligand. Efficiency of particle uptake is further influenced by (i) the invasin fragment and density on the particle, (ii) the stability of its attachment to the carrier, and (iii) the type of nanoparticle (size, mobility, surface charge). Attaching increasing concentrations of invasin onto a latex nanoparticle was shown to increase cell entry and drug carriage. However, after a certain ligand density was reached, less efficient delivery was observed [87] . Use of a longer 497-residue InvA fragment could be also beneficial for uptake, as it induces invasin self-association and  1 -integrins clustering which enhances uptake efficiency [74, 88] . On the other hand, a larger InvA fragment might be more prone to degradation by intestinal proteases [78] .
Moreover, it could be shown in vitro that invasin from Y. pseudotuberculosis induces the apical expression of β 1 -integrins on Caco-2 cells and stimulates the uptake of nanoparticles via invasin-dependent transcytosis [80] .
Another drawback might be the generation of unwanted immune responses.
Invasin-binding to epithelial cells in vitro was found to activate gene expression and to induce the production and secretion of multiple proinflammatory cytokines, including IL-8, IL-1α, IL-1β, monocyte chemoattractant protein 1 (MCP-1), granulocyte macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor alpha (TNF-α) [89] . Invasin has also successfully been used as a vaccine adjuvant, and ovalbumin-InvA-coated microparticles were found to induce ovalbumin-specific CD8 T-cell responses and CD4 T-cell responses (IFN-γ, IL-4) [90, 91] . These properties must not necessarily be disadvantageous for an InvA-based drug delivery system. Firstly, no or only a very weak immune response to InvA was detected in patients suffering from yersiniosis [92] . Since  1 -integrins are expressed on certain phagocytes (e.g. dendritic cells), immune tolerance could be induced [93] . Secondly, cyto-and chemokine induction could induce a more potent immune response and enhance the efficacy of delivered vaccines. In fact, a noninvasive Shigella mutant (ΔipaB) equipped with invasin caused polymorphonuclear cell infiltration in the lung.
However, it did not induce the production of large amounts of proinflammatory cytokines and it was safer and more effective than the conventional live vaccine [94] .
Thirdly, InvA-mediated IL-8 induction, which is typically accompanied by a transient separation of cell-cell contacts, was shown to facilitate access into deeper tissues and improve dissemination [95] . In this regard, IL-8 produced by InvA and many other bacterial invasion factors (e.g. YadA) could support the invasive function.
Summary and future perspectives
The oral route constitutes the preferred route for drug delivery but many drugs, like peptides and proteins, are still poorly available after oral administration. To overcome Although use of bacterial invasins has great potential for particle-based oral drug delivery, many issues need to be considered and addressed to improve this technology. This not only includes the properties of the carrier and the bioactivity of the ligand, it also depends on the effectiveness of a drug delivery system. Bacterial invasins, which promote uptake via β 1 -integrins, would restrict access to M cells and would limit effectiveness. Targeting of other cell types might only be possible under specific conditions, for instance concomitantly to intestinal inflammation (e.g. IBD), when β 1 -integrins become accessible on the apical side of enterocytes due to an opening of the tight-junctions [99] . In this respect, invasin-coated nanoparticles might provide a new possibility to target pharmaceutical compounds for the treatment of IBD.
Since the number of M cells within the intestinal epithelium is usually very low, alternative drug delivery systems targeting different and more abundant intestinal cells are also desirable. Promising alternative candidates for targeting of drug carriers are the listerial internalin proteins. Nanoparticles coated with a fragment of InlA promote uptake into human enterocytes (Caco-2) in a monolayer system [100] .
Moreover, expression of InlA by the food-grade bacterium Lactococcus lactis (used as an antigen delivery vehicle) rendered the cocci capable of invading epithelial cells in vitro as well as in vivo using a guinea pig infection model [101] . A recent study further demonstrated that InlA interacts with E-cadherin receptors which are accessible around mucus-expelling goblet cells (GCs), extruding enterocytes at the tip and lateral sides of intestinal villi, and in villus epithelial folds. The InlA-promoted uptake leads to rapid transcytosis across the intestinal epithelium, and release in the lamina propria by exocytosis [102] . Development and analysis of InlA-based drug delivery systems in mouse models was previously hampered by the fact that InlAmediated invasion was restricted to human cells due to a single amino acid exchange in the murine E-cadherin receptor [103] . However, a mouse model expressing huma-nized E-cadherin was quite recently developed, which now allows in vivo testing [103, 104] .
The inquiry of available genomes of bacterial pathogens further reveals that the choice of alternative bacterial invasins for drug delivery is far from being exhausted. [105] [106] [107] . Whether any of the bacterial ligands will be used for drug delivery in the future is hardly predictable, but their potential for the development of drug delivery system is unquestionable. A more detailed knowledge about their molecular function and in vivo activity will help us to evaluate and prove their merits as drug targeting agents. 
